Ticagrelor Exerts Immune-Modulatory Effect by Attenuating Neutrophil Extracellular Traps

Neutrophils through the release of neutrophil extracellular traps (NETs) containing active tissue factor (TF) are key components of thrombo-inflammation. Platelets-neutrophils interplay in ST elevation myocardial infarction (STEMI) promotes NET formation via inorganic polyphosphates (polyP) released by thrombin-activated platelets. NETs, however, are also induced by biomaterials in a platelet-independent manner. Considering the possible pleiotropic effects of Ticagrelor beyond platelet inhibition and the clinical need for novel antithrombotic strategies targeting inflammation, we investigated the effects of Ticagrelor on polyP and stent-induced NETs in STEMI. Neutrophils from healthy individuals and patients receiving Ticagrelor were stimulated with polyP or drug-eluting stents (DES) to produce NETs. To induce TF expression, neutrophils were further incubated with plasma obtained from the infarct-related artery (IRA) of STEMI patients. The effects of Ticagrelor on NETs and TF loading were assessed using fluorescence microscopy, flow cytometry, myeloperoxidase(MPO)/DNA complex ELISA, and a Western blot. Ticagrelor interrupts platelet–neutrophil interaction by attenuating NETs induced by polyP. However, Ticagrelor does not affect polyP secretion from thrombin-activated platelets. Similarly, the intracellular production of TF in neutrophils triggered by IRA plasma is not hindered by Ticagrelor. Furthermore, DES induce NETs and synchronous stimulation with IRA plasma leads to the formation of thrombogenic TF-bearing NETs. Ticagrelor inhibits stent-induced NET release. These findings suggest a novel immune-modulatory effect of Ticagrelor when it attenuates the formation of thrombogenic NETs.

[1]  Yong Hwan Park,et al.  Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. , 2019, JAMA.

[2]  C. Oury,et al.  Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria. , 2019, JAMA cardiology.

[3]  B. Prendergast,et al.  Safety of drug-eluting stents compared to bare metal stents in patients with an indication for long-term oral anticoagulation: A propensity score matched analysis. , 2019, Thrombosis research.

[4]  Andrew P. Vreede,et al.  Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome , 2019, Nature Communications.

[5]  Andrés Hidalgo,et al.  To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps , 2019, Cell Death and Differentiation.

[6]  I. Mitroulis,et al.  Autophagy in Neutrophils: From Granulopoiesis to Neutrophil Extracellular Traps , 2018, Front. Cell Dev. Biol..

[7]  R. Charnigo,et al.  Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia , 2018, JACC. Basic to translational science.

[8]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[9]  T. Renné,et al.  Host DNases prevent vascular occlusion by neutrophil extracellular traps , 2017, Science.

[10]  M. Maitz,et al.  Neutrophil extracellular trap formation upon exposure of hydrophobic materials to human whole blood causes thrombogenic reactions. , 2017, Biomaterials science.

[11]  Veroniki P. Vidali,et al.  Interferon lambda1/IL‐29 and inorganic polyphosphate are novel regulators of neutrophil‐driven thromboinflammation , 2017, The Journal of pathology.

[12]  L. Feldman,et al.  Bioreactivity of stent material: Activation of platelets, coagulation, leukocytes and endothelial cell dysfunction in vitro , 2017, Platelets.

[13]  M. Werner.  Drug eluting stents and modern stent technologies for in-stent restenosis. , 2017, Journal of Cardiovascular Surgery.

[14]  Anne-Céline Martin,et al.  Ticagrelor reversal: in vitro assessment of four haemostatic agents , 2017, Journal of Clinical Pathology.

[15]  I. Mitroulis,et al.  NETopathies? Unraveling the Dark Side of Old Diseases through Neutrophils , 2017, Front. Immunol..

[16]  Yaqi Zhang,et al.  Role of P2Y12 Receptor in Thrombosis. , 2016, Advances in experimental medicine and biology.

[17]  I. Mitroulis,et al.  Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps , 2015, Antimicrobial Agents and Chemotherapy.

[18]  R. Storey,et al.  Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[19]  H. Horiuchi,et al.  Prostaglandin E2 inhibits neutrophil extracellular trap formation through production of cyclic AMP , 2015, British journal of pharmacology.

[20]  Michael Joner,et al.  Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014 , 2015, European heart journal.

[21]  K. Nelander,et al.  In vitro anti-platelet potency of ticagrelor in blood samples from infants and children. , 2015, Thrombosis research.

[22]  A. Assinger,et al.  Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes , 2015, Thrombosis and Haemostasis.

[23]  R. Storey,et al.  Effect of P2Y12 inhibitors on inflammation and immunity , 2015, Thrombosis and Haemostasis.

[24]  W. Desmet,et al.  Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium† , 2015, European heart journal.

[25]  R. Storey,et al.  Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis , 2015, Vascular pharmacology.

[26]  D. Wagner,et al.  PHAGOCYTES , GRANULOCYTES , AND MYELOPOIESIS P-selectin promotes neutrophil extracellular trap formation in mice , 2015 .

[27]  K. Kolev,et al.  DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment , 2015, Thrombosis and Haemostasis.

[28]  A. Giatromanolaki,et al.  Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction , 2015, European heart journal.

[29]  A. Maseri,et al.  Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps , 2014, Journal of thrombosis and haemostasis : JTH.

[30]  Young-Tae Chang,et al.  In situ investigation of mammalian inorganic polyphosphate localization using novel selective fluorescent probes JC-D7 and JC-D8. , 2014, ACS chemical biology.

[31]  C. Bode,et al.  Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry , 2013, Thrombosis and Haemostasis.

[32]  C. Held,et al.  Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study , 2013, Platelets.

[33]  H. Thorlacius,et al.  Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis , 2013, Platelets.

[34]  M. Krumrey,et al.  Mechanical Stability and Fibrinolytic Resistance of Clots Containing Fibrin, DNA, and Histones* , 2013, The Journal of Biological Chemistry.

[35]  M. Rico,et al.  Prasugrel Metabolites Inhibit Neutrophil Functions , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[36]  N. Jørgensen,et al.  Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo , 2012, Journal of Bone and Mineral Research.

[37]  C. Held,et al.  Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. , 2012, Journal of the American College of Cardiology.

[38]  A. Girod,et al.  Autophagy Mediates the Delivery of Thrombogenic Tissue Factor to Neutrophil Extracellular Traps in Human Sepsis , 2012, PloS one.

[39]  T. Renné,et al.  Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. , 2012, Blood.

[40]  Maria D Jimenez-Nuñez,et al.  Myeloma cells contain high levels of inorganic polyphosphate which is associated with nucleolar transcription , 2012, Haematologica.

[41]  D. Moreno-Sánchez,et al.  Polyphosphate Is a Novel Pro-inflammatory Regulator of Mast Cells and Is Located in Acidocalcisomes* , 2012, The Journal of Biological Chemistry.

[42]  Z. Werb,et al.  Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. , 2012, The Journal of clinical investigation.

[43]  U. Pendurthi,et al.  Tissue factor encryption and decryption: facts and controversies. , 2012, Thrombosis research.

[44]  A. Walch,et al.  Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo , 2012, The Journal of experimental medicine.

[45]  K. Preissner,et al.  Neutrophil Extracellular Traps Directly Induce Epithelial and Endothelial Cell Death: A Predominant Role of Histones , 2012, PloS one.

[46]  Stephanie A. Smith,et al.  Polyphosphate is a cofactor for the activation of factor XI by thrombin. , 2011, Blood.

[47]  D. Boumpas,et al.  Neutrophil Extracellular Trap Formation Is Associated with IL-1β and Autophagy-Related Signaling in Gout , 2011, PloS one.

[48]  P. Vandenabeele,et al.  Neutrophil extracellular trap cell death requires both autophagy and superoxide generation , 2011, Cell Research.

[49]  J. Hartwig,et al.  Extracellular DNA traps promote thrombosis , 2010, Proceedings of the National Academy of Sciences.

[50]  K. Preissner,et al.  Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases , 2010, Nature Medicine.

[51]  W. Ruf,et al.  Neutrophils release brakes of coagulation , 2010, Nature Medicine.

[52]  J. Lambris,et al.  Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. , 2010, Blood.

[53]  T. Renné,et al.  Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In Vivo , 2009, Cell.

[54]  Jun Xu,et al.  Extracellular histones are major mediators of death in sepsis , 2009, Nature Medicine.

[55]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[56]  Z. Werb,et al.  Netting neutrophils in autoimmune small-vessel vasculitis , 2009, Nature Medicine.

[57]  John D Lambris,et al.  C5a and TNF-α Up-Regulate the Expression of Tissue Factor in Intra-Alveolar Neutrophils of Patients with the Acute Respiratory Distress Syndrome1 , 2008, The Journal of Immunology.

[58]  Stephen R. Clark,et al.  Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood , 2007, Nature Medicine.

[59]  E. Oldfield,et al.  Human Platelet Dense Granules Contain Polyphosphate and Are Similar to Acidocalcisomes of Bacteria and Unicellular Eukaryotes* , 2004, Journal of Biological Chemistry.

[60]  K. Schrör,et al.  Specific inhibition of ADP‐induced platelet aggregation by clopidogrel in vitro , 1999, British journal of pharmacology.

[61]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.